We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




MS-Based Immunoassay Detects Levels of Bioactive BNP

By LabMedica International staff writers
Posted on 28 Oct 2008
A novel, quantitative mass spectrometry immunoassay has been developed for the detection of bioactive b-type natriuretic peptide (BNP). More...


A team of scientists discovered very low concentrations of bioactive BNP in plasma obtained from patients with heart failure, and demonstrated direct structural evidence for several proteolytically degraded forms of BNP in these patients.

Intrinsic Bioprobes Inc. (Tempe, AZ, USA) together with colleagues from Scios Inc. (Fremont, CA, USA), Christ Hospital (Cincinnati, OH, USA), and Medivation Inc. (San Francisco, CA, USA) reported their findings in an article that appeared in the October 14, 2008 journal Circulation: Heart Failure.

Commercially available assays for immunoreactive BNP do not reflect the bioactivity of the natriuretic peptide system, since they measure both unprocessed, inactive proBNP and mature BNP 1-32," said Eric Niederkofler, Ph.D., the principal investigator from Intrinsic Bioprobes. BNP is synthesized as a 108 amino acid propeptide and proteolytically processed to release an inactive 76 amino acid N-terminal fragment and bioactive mature BNP 1-32 into the bloodstream.

"This is the first assay capable of detecting and quantifying BNP 1-32 alone. Furthermore, the assay allowed us to study the molecular complexity of BNP degradation, revealing rapid in vitro degradation of BNP 1-32, and necessitating certain preservation protocol during blood collection and subsequent sample handling,” added Dr. Niederkofler.

Intrinsic Bioprobes Inc. is a privately held biotechnology company focused on developing mass spectrometry-based assays and platforms for rapid and sensitive protein biomarker analysis. The company's proprietary technologies consist of Mass Spectrometric Immunoassay (MSIA), a high-performance immunoassay combining micro-scale immunoaffinity capture and mass spectrometry for high throughput analysis of proteins from complex biological matrices, and bioreactive mass spectrometer probes (BRP), devices for rapid, sensitive and accurate protein characterization. These root technologies are incorporated into the MASSAY System, a high-throughput mass spectrometry platform for rapid proteome analysis.

Related Links:
Intrinsic Bioprobes
Scios Inc.
Christ Hospital
Medivation Inc.


Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Microbiology

view channel
Image: The model estimated about a fivefold return in gastric cancer prevention benefits per unit invested, with cost-effectiveness maintained in higher-cost settings (Image credit: Adobe Stock)

H. pylori Screening Within Colorectal Program Aids Gastric Cancer Prevention

Health systems increasingly rely on economic evidence to guide cancer prevention strategies. For gastric cancer, selecting screening approaches that can integrate with existing programs is a key policy question.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.